Skip to main content
. 2021 Jul 15;10:100067. doi: 10.1016/j.ynpai.2021.100067

Fig. 3.

Fig. 3

Selection of lead CCK-BR scFv 77-2 dose that alleviates neuropathic pain in 2 rodent models and time points. A. Single 4 mg/kg i.p. injection of 77-2, 14-3, and 134-1 scFvs in week 3 reversed orofacial pain shown for male mice [F(72, 175) = 76.05]. B. Dose response effect of scFv 77-2 for reversal of ipsilateral trigeminal nerve mechanical hypersensitivity (0.04, 0.4, 4 and 40 mg/kg). Zika and low dose CCK-BR (0.04 mg/kg) scFvs were ineffective, shown for male mice [F(78, 474) = 171.80] C. scFv 77-2 was equally effective in males and females. [F(39, 361) = 212.80] D. Single dose (4 mg/kg) CCK-BR scFv was effective in alleviating the SNI model as well, as shown for male mice. Data was identical when CCK-BR scFv 77-2 was given at a later time point (7 weeks). [F(18, 130) = 20.76] ** indicates a p-value of < 0.01, *** indicates a p-value of < 0.001]. In post-hoc analyses, Bonferroni adjustment to all p-values for week-by-week comparisons of FRICT-ION versus naïve control yields p-values < 0.001 for all.